KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Total Non-Current Liabilities: 2010-2024

Historic Total Non-Current Liabilities for Pacira BioSciences (PCRX) over the last 15 years, with Dec 2024 value amounting to $754.9 million.

  • Pacira BioSciences' Total Non-Current Liabilities fell 27.61% to $545.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $545.1 million, marking a year-over-year decrease of 27.61%. This contributed to the annual value of $754.9 million for FY2024, which is 11.09% up from last year.
  • Per Pacira BioSciences' latest filing, its Total Non-Current Liabilities stood at $754.9 million for FY2024, which was up 11.09% from $679.6 million recorded in FY2023.
  • Pacira BioSciences' Total Non-Current Liabilities' 5-year high stood at $1.3 billion during FY2021, with a 5-year trough of $641.2 million in FY2020.
  • For the 3-year period, Pacira BioSciences' Total Non-Current Liabilities averaged around $770.9 million, with its median value being $754.9 million (2024).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 100.77% in 2021, then plummeted by 31.79% in 2022.
  • Yearly analysis of 5 years shows Pacira BioSciences' Total Non-Current Liabilities stood at $641.2 million in 2020, then spiked by 100.77% to $1.3 billion in 2021, then tumbled by 31.79% to $878.1 million in 2022, then decreased by 22.61% to $679.6 million in 2023, then rose by 11.09% to $754.9 million in 2024.